



## NSX ANNOUNCEMENT

12 July 2024

### Pre-Quotation Disclosure

GO-Dx Corporation (Aust) Ltd (ACN 673 839 613) (**Company**) provides the following confirmations and information to satisfy conditions for the admission of the Company to the Official List of NSX and the quotation of the Company's securities.

Capitalised terms in this announcement have the same meaning as given under the Company's Supplementary Prospectus dated 30 May 2024 (**Supplementary Prospectus**) and Replacement Prospectus dated 15 March 2024 (**Replacement Prospectus**), unless the context otherwise requires.

#### 1. Completion of Offer

The Company confirms that the Offer has closed and that the shares under the Offer have been allotted. Pursuant to the Offer, the Company raised \$514,330 from investors for the issue of 1,353,500 Shares.

#### 2. Updated Use of Funds

As set out in the Company's Supplementary Prospectus, the Company revised its Minimum Subscription amount for the purposes of the Offer. The decision to reduce the Minimum Subscription was made in response to the challenging capital market conditions and the current economic environment.

The Company remains focused on achieving its goals and delivering value for investors. The Company considers that it will be able to achieve its goals in developing its products and other objectives based on the funds raised under the Offer and the Company's existing cash reserves.

The Company's updated Use of Funds table based on the funds raised under the Offer is as follows:

Use of Funds	Minimum Subscription	%
Further development and commercialisation of the RNA Mapping Platform and RNA Analytical Platform	50,000	9.7%
Development of an AI-Enabled Platform	60,000	11.7%
Further development and clinical validation of miRNA based biotechnologies for liquid biopsies for cancers	50,000	9.7%
Development of the intellectual property licensed to the Company to create novel inventions for the Company's use and exploitation	25,000	4.9%
Completing the Pathomics Health Investment	55,469	10.8%
Market launch initiatives	25,000	4.9%
Research and Development	30,000	5.8%
Management costs	60,000	11.7%
General working capital requirements	158,861	30.9%
	<b>\$514,330</b>	<b>100%</b>

As a result of the revised Minimum Subscription, the Company reduced its investment in Pathomics Health (by agreement with Pathomics Health) and reduced its other budgeted amounts for management administrative expenses, marketing and research and development activities associated with its Products and technologies.

Originally the Company had agreed to acquire 10% of the issued capital in Pathomics Health for a total of SGD\$1,150,000 to be paid for in 3 tranches. The Company had paid SGD\$150,000 to Pathomics Health towards the tranche 1 investment of SGD\$200,000 to purchase 1.9% of Pathomics Health (refer to summary of Share Subscription Agreement on page 89 of Replacement Prospectus).

Under the variation agreed with Pathomics Health, the Company shall now pay a further SGD\$50,000 to complete the tranche 1 investment in accordance with the Share Subscription Agreement with no current obligation to proceed with the tranche 2 and tranche 3 subscriptions into Pathomics Health. The Company will consider further investment into Pathomics Health in the future if and when the Company raises further capital.

Following Admission, the Company will be working closely with Pathomics Health in co-developing new laboratory tests in the diagnostics sectors as part of its Business Collaboration Agreement and in co-developing an AI-platform to increase and enhance genetic, transcriptomics and epigenetic data analysis and processing under its AI-platform collaboration agreement (refer to page 90 of Replacement Prospectus).

Following Admission, the Company will commence marketing activities and launch its RNA Mining/Mapping Platform to clients, referral partners and distribution channels in the Singapore market. As detailed in the Company's Replacement Prospectus, the RNA Mining/Mapping Platform is a functioning product which has been developed to a commercialisation stage.

The Company will continue research and development activities on a reduced scale and its' goals still remain the same in terms of ongoing development and improvement of its RNA Mining/Mapping Platform.

Furthermore, following Admission the Company intends to generate revenues from the supply and distribution of its Products via the supply and distribution agreements that it has entered into (as referred to in Material Contracts section of Replacement Prospectus). The revenues generated from the sales of Products under the supply and distribution agreements may be used towards funding the further development of the RNA Mining/Mapping Platform and other Company expenses.

### **3. Potential for Future Capital Raisings**

The Company will continue to raise capital from the equity capital markets in the future as a listed company on the NSX.

The Company may raise further capital from investors in the next 12 months if required in order to provide additional funding for further business growth initiatives, potential commercial opportunities that may arise and any ongoing business requirements.

As part of its future capital raising plans, the Company may also provide an opportunity for shareholders to participate in future capital raisings by making pro-rata entitlement offers to shareholders.

Any future capital raisings undertaken will be in compliance with the NSX Listing Rules and Corporations Act requirements.